People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| IntraBio Inc | — | Biotechnology | Series C | $50.6M | $460.0M | 2023 |
MARK C. LUBKEMAN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MARK C. LUBKEMAN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JAMES C. MEYERS | 1 | 2 |
| CHRISTIAN C. YEGEN | 1 | 1 |
| MALLORY FACTOR | 1 | 1 |
| IAN C. BILLINGTON | 1 | 1 |
| IAN C. ROSEN | 1 | 1 |
| ALI C. KHAN | 1 | 1 |
| TAYLOR C. FIELDS | 1 | 1 |
| ELIZABETH FACTOR | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.